UroMems
Develops a next-generation implantable medical device to treat urinary incontinence, aiming to improve patient outcomes and expand therapeutic options.
Overview
UroMems is a French medical-device startup developing a next-generation implant to treat urinary incontinence. The company focuses on an implantable therapeutic option intended for patients with urinary incontinence and the clinicians who manage continence care, positioning the product as an alternative to existing non-invasive and device-based approaches. In May 2026 UroMems secured $60 million in an undisclosed round led by Ajax Health, representing the company's total disclosed financing to date. The capital is described as support for advancing the implant’s development and preparation for broader clinical and commercial milestones.
Funding History
French startup UroMems secures $60M from Ajax Health for next-gen urinary incontinence implant
Frequently Asked Questions
- How much funding does AI Funding track for UroMems?
- AI Funding tracks $60M for UroMems across 1 funding round in this database.
- Who are UroMems's investors?
- UroMems's investors include Ajax Health.
- What does UroMems do?
- UroMems is a French medical-device startup developing a next-generation implant to treat urinary incontinence. The company focuses on an implantable therapeutic option intended for patients with urinary incontinence and the clinicians who manage continence care, positioning the product as an alternative to existing non-invasive and device-based approaches. In May 2026 UroMems secured $60 million in an undisclosed round led by Ajax Health, representing the company's total disclosed financing to date. The capital is described as support for advancing the implant’s development and preparation for broader clinical and commercial milestones.
- Where is UroMems headquartered?
- UroMems is headquartered in France.
Investors
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.